Filing search / Centessa Pharmaceuticals plc / "Strategy"

8-K

EX-99.2

CNTA Centessa Pharmaceuticals plc

10 Sep 24

Regulation FD Disclosure

7:08am

, SerpinPC, ORX750, ORX142 and, LB101; strategy; regulatory matters, including the timing and they should not be relied upon as an accurate prediction

8-K

EX-99.1

CNTA Centessa Pharmaceuticals plc

10 Jun 24

Departure of Directors or Certain Officers

7:13am

financial executive with deep technical knowledge and experience in driving financial strategy, operations and planning. He will be an invaluable asset

DEFA14A

CNTA Centessa Pharmaceuticals plc

20 May 24

Additional proxy soliciting materials

8:48pm

of our business.” – p.89. Description of the company’s strategy and business model Part I, Item 1: Business; Overview – p.5 Part I, Item 1: Business; Our … are important to the Group’s growth strategy and align with the Group’s values of integrity and equality. Appointments within the Group are made

PRE 14A

tj824wnr

26 Apr 24

Preliminary proxy

4:36pm

424B5

75z902irtgaosc3fzw

24 Apr 24

Prospectus supplement for primary offering

8:53pm

424B5

d4kdr01zcqwwgv8

23 Apr 24

Prospectus supplement for primary offering

5:16pm

8-K

EX-99.2

l2ihm4oo

22 Apr 24

Regulation FD Disclosure

7:15am

8-K

EX-99.1

zxtl hrtyrgk14mh9aui

9 Feb 24

Regulation FD Disclosure

7:12am

8-K

EX-99.1

96gyl9d

9 Jan 24

Regulation FD Disclosure

7:56am

8-K

EX-99.2

dijjw767xt 0t

25 Oct 23

Regulation FD Disclosure

9:49am

8-K

EX-99.1

t6ellj8

25 Oct 23

Regulation FD Disclosure

9:49am

8-K

EX-99.2

yx9ab hn7blkylc

14 Aug 23

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

7:06am

8-K

EX-99.1

4hw31 cppuvtze5l3u

9 Jun 23

Regulation FD Disclosure

7:10am

DEFA14A

wumy75

23 May 23

Additional proxy soliciting materials

4:08pm